



Rossello, X., Ferreira, J. P., Pocock, S. J., McMurray, J. J.V., Solomon, S. D., Lam, C. S.P., Girerd, N., Pitt, B., Rossignol, P. and Zannad, F. (2020) Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. *European Journal of Heart Failure*, 22(5), pp. 834-844.

There may be differences between this version and the published version. You are advised to consult the publisher's version if you wish to cite from it.

This is the peer reviewed version of the following article Rossello, X., Ferreira, J. P., Pocock, S. J., McMurray, J. J.V., Solomon, S. D., Lam, C. S.P., Girerd, N., Pitt, B., Rossignol, P. and Zannad, F. (2020) Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. *European Journal of Heart Failure*, 22(5), pp. 834-844, which has been published in final form at <https://doi.org/10.1002/ejhf.1740>. This article may be used for non-commercial purposes in accordance with [Wiley Terms and Conditions for Self-Archiving](#).

<https://eprints.gla.ac.uk/211678/>

Deposited on: 16 February 2022

Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials

Short title: Sex differences in MRA trials

Xavier Rossello, MD, PhD^{1,2,3}; João Pedro Ferreira, MD, PhD⁴; Stuart J Pocock, PhD⁵; John JV McMurray, MD, PhD⁶; Scott D. Solomon, MD, PhD⁷; Carolyn SP Lam, MD, PhD⁸; Nicolas Girerd, MD, PhD⁴; Bertram Pitt, MD, PhD⁹; Patrick Rossignol, MD, PhD⁴; Faiez Zannad, MD, PhD⁴

¹ Department of Cardiology, Hospital Universitari Son Espases (HUSE), Mallorca, Spain; ² Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain; ³ CIBER de enfermedades Cardiovasculares (CIBERCV), Madrid, Spain; ⁴ Université de Lorraine, Centre d'Investigation Clinique-Plurithématique Inserm CIC-P 1433, and Inserm U1116, CHRU Nancy Brabois, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France; ⁵ London School of Hygiene and Tropical Medicine, London, United Kingdom; ⁶ BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK; ⁷ Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, MA, USA; ⁸ National Heart Centre Singapore, Singapore; ⁹ Department of Medicine, University of Michigan School of Medicine, Ann Arbor, USA

Abstract word count: 248

Manuscript word count: 3185

Address for correspondence

Dr. Faiez Zannad, Centre d'Investigations Cliniques – INSERM CHU de Nancy, Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu, 4 Rue du Morvan, Vandoeuvre lès Nancy 54500, France.

Tel: +33 383157322/20 ; Fax: +33 383157324; Email: f.zannad@chu-nancy.fr

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/ejhf.1740](https://doi.org/10.1002/ejhf.1740)

Abstract

AIMS. Women with heart failure (HF) are under-represented in individual randomized clinical trials (RCTs). Little is known about sex-specific treatment effects in HF medications.

We evaluated sex differences in the response to mineralocorticoid receptor antagonists (MRAs) in major HF MRA trials, including a broad spectrum of left ventricular ejection fraction (LVEF).

METHODS AND RESULTS. Individual-patient data fixed-effect meta-analysis was performed using 6,167 patients (31.4% were women) recruited in three placebo-controlled RCTs: Randomized Aldactone Evaluation Study (RALES), Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) and the Spironolactone for Heart Failure with Preserved Ejection Fraction (TOPCAT)-Americas. Compared to men, women were older, had higher body mass index and lower glomerular filtration rate. They also had higher LVEF and poorer NHYA functional class and were less likely to be taking angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers. Placebo-arm event rates were lower for women compared with men (15.4 vs. 22.1 per 100-person-year; $p=0.002$). MRAs reduced consistently, in men and women, the relative risk for cardiovascular death or heart failure hospitalization (p -for-interaction=0.83), cardiovascular death (p -for-interaction=0.44) and all-cause death (p -for-interaction=0.19). These findings remained consistent after adjustment for potential confounders, regardless of the LVEF. There was no sex-specific impact of MRA on the rate of hyperkalemia and worsening renal function during the median 22 months of follow-up.

CONCLUSION. In three large MRA RCTs, women were substantially different than men with regards to their clinical features and event rates. Nonetheless, this meta-analysis supports a consistent and beneficial MRA effect regardless of sex.

Keywords

Heart failure; mineralocorticoid receptor antagonists; meta-analysis; women

Introduction

Current guidelines recommend the use of mineralocorticoid receptor antagonists (MRAs) in patients with symptomatic heart failure (HF), left ventricular ejection fraction (LVEF) $\leq 35\%$ and New York Heart Association (NYHA) class II–IV, based on the results of the Randomized Aldactone Evaluation Study (RALES)¹ and the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure trial (EMPHASIS-HF)², supported by the findings of the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) trial³. Treatment with spironolactone did not show a reduction in the incidence of the time-to-first composite of cardiovascular death, aborted cardiac arrest or HF hospitalizations in patients with LVEF $\geq 45\%$ in the Spironolactone for Heart Failure with Preserved Ejection Fraction (TOPCAT) trial⁴; however, important regional differences in patient characteristics, event-rates, drug adherence and treatment effect were identified. Patients in two countries (Georgia and Russia) had low event rates, inconsistent with HFpEF and adherence in those countries was poorer than elsewhere^{5–7}.

Some controversy has arisen in HF pharmacotherapy in light of the recent findings provided by the Prospective Comparison of ARNI [angiotensin receptor–neprilysin inhibitor] with ARB [angiotensin-receptor blockers] Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial, where a subgroup analysis suggested an heterogeneity of treatment effect with possible benefit of ARNI in women compared to men⁸. These findings should be considered in the context of the Prospective Comparison of ARNI with ACEI [Angiotensin-Converting–Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF) trial, which had nearly identical entry

criteria apart from a lower LVEF and showed no interaction in treatment effect between women and men⁹.

There are many differences between men and women with HF¹⁰. Women with HF_rEF have a better survival than men with the same condition and the same is true for HF_pEF^{11,12}. Moreover, women are, on average, older than men, have less coronary heart disease but more hypertension^{11,12}. They have also worse symptoms and worse renal function and receive less evidence-based therapy than men¹³. These differences raise the possibility of a difference between men and women in relation to the efficacy or tolerability of HF treatments, such as ARNI or MRAs. This possibility has been difficult to evaluate as subgroups in individual trials are, by definition, underpowered, especially as women represent the minority of patients^{14,15}. A meta-analytical approach helps mitigate this limitation.

We performed a meta-analysis, using individual patient data from three large randomized clinical trials (RALES, EMPHASIS-HF and TOPCAT), to assess the sex-specific responses to MRA treatment in individuals with HF across a broad spectrum of ejection fraction.

Methods

Study design, setting and participants

We pooled data from three placebo-controlled RCTs: RALES (NYHA class III-IV with LVEF \leq 35%)¹, EMPHASIS-HF (NYHA class II with LVEF \leq 35%)² and TOPCAT (heart failure signs and symptoms with LVEF \geq 45%)⁴. **Table S1** shows the main features of each trial, including inclusion/exclusion criteria, medication (spironolactone or eplerenone),

primary endpoint and duration of follow-up. Given regional disparities described in TOPCAT, subsequent *post hoc* analyses of TOPCAT have been restricted to the patients randomized in other countries (all in Latin and North America)^{6,7}, where patients had characteristics compatible with HFpEF and high proportion of detectable circulating levels of spironolactone metabolites. Therefore, we used only data from the “Americas” (United States, Canada, Brazil, and Argentina), excluding those from Russia and Georgia.

Each individual RCT was conducted in accordance with the Declaration of Helsinki¹⁶ and approved by site ethics committees. All participants gave written informed consent to participate in the RCTs.

Study outcomes

The primary outcome used in the present analysis was the composite of cardiovascular death or HF hospitalization. Secondary outcomes included cardiovascular death and all-cause mortality. These clinical outcomes were centrally adjudicated by endpoint committees with broadly consistent definitions across the trials^{1,2,4}.

Hyperkalemia was defined as any laboratory value of serum potassium above 5.5 mmol/L during follow-up and worsening renal function was defined as a decline of more than 30% in estimated glomerular filtration rate (eGFR) during follow-up.

Statistical analysis

Baseline clinical features between men and women were described as frequency (%) and compared using chi-square tests for categorical data, whereas baseline continuous data were expressed as mean and standard deviation (SD) and compared using t tests. The normal distribution of continuous data subset was evaluated using graphical methods.

Incidence rates for men and women (in each of the two treatment groups), as well as incidence rates ratios (for estimating relative risk reduction) and difference in rates (for estimating absolute risk reduction) were estimated for each HF phenotype and for the overall pooled sample. The number needed to treat (NNT) at 3 years was estimate using the inverse of the absolute risk reduction and their 95% confidence interval (95% CI).

Baseline time was defined by the timing of randomization (Table S1), which was (1) within 6 months of meeting the inclusion criteria for RALES; (2) within 6 months after hospitalization for a cardiovascular reason for EMPHASIS-HF; and (3) within 12 months after hospitalization for heart failure or with an elevated natriuretic peptide level within 60 days before randomization (brain BNP ≥ 100 pg/mL or NTproBNP ≥ 360 pg/mL). Kaplan-Meier curves for the composite endpoint of cardiovascular death or heart failure hospitalization were obtained for each subgroup (male-placebo, male-MRA, female-placebo and female-MRA) within each HF phenotype using the Kaplan–Meier method. Cox proportional hazards modelling was used to assess the treatment effect in the overall pooled sample as well as to explore whether this effect was consistent between men and women (adding the interaction MRA * gender) into the model and reporting the p for interaction. Hazard ratios (HRs) with their 95% CI were used for treatment effect estimates. The model was stratified by study, which assumes equal effects across strata but with a baseline hazard unique to each study^{17,18}.

A fixed-effect model for a one-stage individual patient data meta-analysis was conducted based on the assumption that the underlying relative treatment effect was similar across trials¹⁹. In order to obtain an adjusted estimate of the effect of MRA for men and

women separately, a set of covariates were chosen according to their clinical relevance or historical association with the outcome in previous studies^{18,20}: MRA, gender, age, race, systolic blood pressure, diabetes, hypertension, atrial fibrillation, ischemic cause, NYHA class III-IV, LVEF, potassium, eGFR, diuretics, ACEI or ARB, beta-blockers and the interaction (*MRA x gender*). Further subgroup evaluations for the primary outcome were performed with a Cox model stratified by study, using the adjusted model and adding a three-way interaction for three clinically relevant patient subsets (age>75 y.o, diabetes and eGFR<60).

Visual inspection of individual effect sizes and overall effect size estimations and their 95% CI were used to identify substantial variation in treatment effect estimates across trials beyond the variation expected by chance alone (statistical heterogeneity). Heterogeneity was formally tested using a 2 degree of freedom Wald test of the overall interaction *study x treatment x gender*.

Logistic regression models were used to assess whether the number of adverse events (hyperkalemia and worsening renal function) were consistent between men and women at the end of the follow-up. An interaction term (*MRA x gender*) was used to report whether adverse events differed by gender and the statistical significance was determined by the relevant p for interaction.

The two-tailed significance level was set at 5%. STATA software version 15.1 (Stata Corp, College Station, TX, USA) was used to perform the analyses and produce most graphs. XR had full access to all the data in the study and takes responsibility for its integrity and the data analysis.

Results

Sex differences in baseline variables

Individual patient data from the three randomised trials (RALES, EMPHASIS-HF and TOPCAT-Americas) were available for 6,167 patients. Of these, 4,229 (68.6%) were men (2,127 and 2,102 randomly allocated to placebo and MRA, respectively) and 1,938 (31.4%) were women (968 and 970 randomly assigned to placebo and MRA, respectively). The median follow-up was 22 months (interquartile range 9-33 months) (the individual follow-up times of each RCT are given in **Table S1**).

Baseline clinical features, medical history, laboratory findings and background treatment at randomization, according to sex, are shown in **Table 1**. Generally, women were older (35.4% vs 25.3% were >75 years) and had higher BMI and poorer renal function (51.8% vs 38.3% had eGFR<60 ml/min/1.73 m²). Women more frequently had a history of hypertension, but less often a history of MI, atrial fibrillation and COPD. Women also had a significantly higher mean LVEF (32.3% vs 41.7%) and poorer overall NHYA functional class. They were also less likely to be treated with an ACEI or ARB (86.0% vs 90.6%), but there were no significant differences between men and women regarding beta blocker and diuretic use. These data stratified by HF type (HF_rEF vs HF_pEF) are presented in **Table S2**.

Unadjusted treatment effect

Overall and by-HF phenotype Kaplan-Meier curves for cardiovascular death or heart failure requiring hospitalization are described in **Figure 1** and **Figure 2**, respectively. The unadjusted incidence rate ratios and incidence rate differences are shown in **Table 2**. The

effect of MRA therapy on the primary outcome was consistent between men and women overall and within each HF phenotype, though the relative risk reduction was greater in HFrEF compared with HFpEF. Consequently, the “absolute “ reduction in number of events was greater in the subset of patients from RALES (NYHA III-IV; LVEF \leq 35%) and EMPHASIS-HF (NYHA II, LVEF \leq 35%) in comparison to those in TOPCAT-Americas (LVEF \geq 45%), although the effect did not differ between men and women within each trial cohort (**Table S2**).

After pooling the data, the primary outcome of cardiovascular death or HF hospitalization occurred in 798 men (37.5%) and 330 women (34.1%) taking placebo (p=0.002), and in 602 men (28.6%) and 251 women (25.9%) taking a MRA. The overall unadjusted HR (95% CI) was 0.70 (0.64-0.76), and was consistent between men (HR 0.69; 95% CI: 0.62-0.77) and women (HR 0.71; 95% CI: 0.60-0.83), as shown in **Figure 3** (p for interaction 0.83). The overall absolute risk reduction of the primary composite outcome at 3 years was 10%, which provides an NNT of 10 (95% CI: 8-14) patients at 3 years to avoid one event, and was consistent between men (NNT 10; 95% CI: 8-15) and women (NNT 10; 95% CI: 7-19).

The risk reductions in secondary outcomes were also relatively consistent between men and women (**Tables 3** and **Table 4**). For cardiovascular death, the unadjusted HR (95% CI) was 0.75 (0.65-0.86) for men and 0.67 (0.54-0.85) for women (p for interaction 0.44), whereas for all-cause mortality the unadjusted HR (95% CI) was 0.80 (0.71-0.90) for men and 0.69 (0.56-0.84) for women (p for interaction 0.19).

Adjusted treatment effect

After adjustment for baseline co-variates (gender, age, race, systolic blood pressure, diabetes, hypertension, atrial fibrillation, non-ischemic cause, NYHA class III-IV, LVEF, potassium, estimated glomerular filtration rate, diuretics, ACEI or ARB treatment, beta-blocker treatment), the treatment effect remained relatively consistent between men and women and within the HFrEF and HFpEF phenotypes (**Figure 3**): the MRA vs placebo HR (95% CI) was 0.65 (0.58–0.74) for men and 0.67 (0.54-0.83) for women with HFrEF and 0.85 (0.67–1.08) for men and 0.83 (0.64-1.07) for women with HFpEF . In the adjusted analysis of all patients, irrespective of LVEF, MRA treatment reduced the risk of cardiovascular death or heart failure hospitalization by 31% in men (HR=0.69; 95% CI: 0.62-0.77) and by 27% in women (HR=0.73; 95% CI: 0.62-0.86).

Statistical heterogeneity

The individual effect size for each trial and overall effect size estimations and their 95% CI depicted in **Figure S1** already suggest the lack of substantial statistical heterogeneity between RALES and EMPHASIS-HF cohorts. Similarly, the individual effect size for HFrEF and HFpEF subject depicted in **Table 2** and **Figure 3** also suggest lack of statistical heterogeneity. The hypothesis of little heterogeneity is also supported by the Wald test for overall interaction *study x treatment x gender* ($p = 0.61$).

Subgroup analyses

Treatment effect was consistent between men and women across the three prespecified subgroups examined i.e. age>75 vs age≤75 years, diabetes vs no diabetes and eGFR<60 vs eGFR ≥60 ml/min/1.73m² after adjustment for baseline covariates (**Figure 4**).

Adverse event effects

Differences in adverse events between men and women were consistent across treatment arms (**Table 5**). There were no significant sex-related differences in the rate of hyperkalemia either in the placebo arm or the MRA arm (p for interaction = 0.94). By contrast, women more often had worsening renal function over follow-up in the placebo arm, though the between treatment group differences were similar by sex (p for interaction = 0.81).

Discussion

In this meta-analysis using individual patient-level data, including 6,167 subjects, representing the full spectrum of LVEF, we found that: 1) women differed substantially from men with respect to baseline characteristics (they were older, had a higher BMI, poorer renal function and fewer co-morbidities, except for hypertension), had a higher mean LVEF, poorer NHYA functional class and were less likely to be treated with an ACEI or ARB); 2) men were at higher risk of events than women; 3) MRA consistently reduced the risk for cardiovascular death and heart failure hospitalization after a mean follow-up of 22 months; 4) by-sex treatment effect remained consistent after adjustment for potential confounders, confirming the lack of interaction between treatment effect and sex; 5) treatment effect was consistent between men and women across the three subgroups of patients studied (age>75, diabetes and eGFR<60) after adjustment for baseline covariates; and 6) there was no sex-specific impact of MRA on hyperkalemia and worsening renal function.

Men and women differ in relation to the physiology of their cardiovascular system (i.e. body composition and role of hormonal changes²¹), in risk factors for cardiovascular

disease, presentation with cardiovascular disease and outcomes from cardiovascular disease. Moreover, there are also sex-related differences in the pharmacokinetics and pharmacodynamics among some of widely used cardiovascular drugs^{10,22}. Thus, it is important to understand the sex-specific efficacy and tolerability of any therapy for cardiovascular disease. However, this type of analysis requires a dataset large enough to give statistically powered information. This issue is illustrated by the results of early trials with ACEI suggesting a benefit only in men²², when subsequent meta-analyses with greater statistical power showed no sex-related difference in treatment effect²³. In contrast, we have incipient but apparently contradictory information from a younger drug (ARNI) in HFpEF: the PARAGON-HF trial reported a subgroup analysis suggesting an heterogeneity of treatment effect with possible benefit of ARNI in women with respect to men (rates ratios of 0.73 and 1.03 for the composite outcome of total hospitalizations for heart failure and cardiovascular death, respectively)⁸, whereas the PARADIGM-HF trial, which had nearly identical entry criteria apart from a lower LVEF, showed no interaction in treatment effect between women and men⁹. Notably, women (who represent a high proportion of HFpEF proportion of patients) were far more represented in the PARAGON-HF trial (51.7%) in comparison to the PARADIGM-HF trial (21.8%), though absolute numbers were more similar between trials. Importantly, we found that the benefit of MRA therapy was consistent between men and women across three large RCTs.

In line with the previous reports^{11-13,24}, and as described above, there were many differences in the baseline characteristics of men and women. Our baseline characteristics data match those reported in the “real-world” by the Swedish Heart Failure Registry¹⁵:

women were older, and more symptomatic and more likely to have hypertension and poor renal function than men. Despite they show that women had a higher crude risk of mortality and morbidity in HFpEF¹⁵, their results after adjustment are in line with our findings showing that women have a lower crude risk for poor outcomes regardless of LVEF, though less differences between men and women are observed in our HFrEF subset of patients. Importantly, the treatment benefit of MRA therapy did not change substantially after adjusting for these and other potential confounders, which have an impact on clinical outcomes and are unevenly distributed between men and women.

At first sight, our results appear to contradict a recent secondary analysis from the TOCAT-Americas suggesting a potential reduction in all-cause mortality associated with spironolactone in women that was not observed in men after adjustment for potential confounding (HR were 0.66 and 1.06 for women and men, respectively; p for interaction 0.024)²⁵. Of note, this analysis did not find a significant interaction for the primary endpoint or other outcomes, including cardiovascular mortality, which seems much more appropriate to study the treatment effect provided by MRA, as we should expect little gain on non-cardiovascular causes of death by administering MRAs. It is likely that this reflects a spurious, chance-finding reflecting the small numbers of events in the TOPCAT-Americas analysis, a conclusion supported by the finding of a mortality benefit from MRA therapy in our much larger and statistically more robust study. A different pathophysiology in women¹⁰⁻¹² or a simple regression to the mean might other less likely explanations for the disagreement between our findings and those reported by Merrill and colleagues²⁵. Some ongoing studies, such as the Spironolactone Initiation Registry Randomized Interventional

Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT) (NCT02901184) and the SPIRONolactone In the Treatment for Heart Failure (SPIRIT-HF) (EudraCT 2017-000697-11) may shed some light on the issue of whether MRA has a different treatment effect between men and women in HFpEF.

We examined 3 clinically important subgroups of patients at particularly high risk of events and in which there is often concern about using MRA therapy i.e. the elderly, patients with diabetes and those with a low eGFR. We found that there was no evidence of a sex-related difference in either the efficacy or safety of MRA therapy in these subgroups.

In line with previous reports²⁶, our findings on adverse event effects underscore the need to measure serum potassium and creatinine levels serially and to accordingly adjust the dose of MRA regardless the gender of the patient. Other factors, such as the eGFR, have a greater impact on the rate of side-effects and drug discontinuation and should be taken into account to adjust for the dose of MRAs, and more broadly RAASi ^{27,28}.

Study limitations

We did not include a number of small trials which studied MRA treatment in patients with HF, because these had few events and are unlikely to alter our conclusions. We also combined two HFrEF trials with a HFpEF trials when these two HF phenotypes are distinct and do not respond to all therapies in a similar manner. Finally, our results are based on the assumption that MRAs represent a 'class effect' ²⁹, although spironolactone and eplerenone differ in their molecular structure, pharmacokinetics and pharmacodynamics.

Conclusions

In this large meta-analysis using individual patient data, women were substantially different from men with regards to their clinical features and events. Nevertheless, MRA treatment led to consistent reductions in the risk for cardiovascular death and heart failure hospitalization, cardiovascular death alone and all-cause death, in both men and women, regardless their NYHA class, LVEF and other confounding factors. Treatment-related hyperkalemia and worsening renal function did not vary by sex. Both men and women can benefit from optimizing the use of an MRA treatment, which is commonly underused in routine practice. These findings are particularly important in the light of recent findings suggesting a different treatment effect between men and women with some HF drugs, such as ARNI.

Funding

XR has received support from SEC-CNIC CARDIOJOVEN Program. JF, NG, PR, FZ are supported by the French National Research Agency Fighting Heart Failure (ANR-15-RHU-0004), by the French PIA project «Lorraine Université d'Excellence » GEENAGE (ANR-15-IDEX-04-LUE) programs, and the Contrat de Plan Etat Région Lorraine and FEDER IT2MP.

Conflict of interest

XR, JPF and SJP have nothing to disclose. JMcM reports conflicts of interest from Roche Pharmaceuticals, during the conduct of the study; other from Novartis, Cardioentis, Amgen Oxford University/Bayer, GlaxoSmithKline, Theracos, Abbvie, Dal-Cor, Pfizer, Merck, AstraZeneca Bristol Myers Squibb (BMS), Kidney Research UK (KRUK)/Kings College Hospital, London/Vifor-Fresenius Pharma, outside the submitted work. SS has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lone Star Heart, Mesoblast, MyoKardia, NIH/NHLBI, Novartis, Sanofi Pasteur, Theracos, and has consulted for Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, BMS, Cardior, Corvia, Cytokinetics, Daiichi-Sankyo, Gilead, GSK, Ironwood, Merck, Myokardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AoBiome, Janssen, Cardiac Dimensions, Tenaya. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, and Vifor Pharma; has served as consultant or on the Advisory Board/ Steering

Committee/ Executive Committee for Boston Scientific, Bayer, Roche Diagnostics, AstraZeneca, Medtronic, Vifor Pharma, Novartis, Amgen, Merck, Janssen Research & Development LLC, Menarini, Boehringer Ingelheim, Novo Nordisk, Abbott Diagnostics, Corvia, Stealth BioTherapeutics, JanaCare, Biofourmis, Darma, Applied Therapeutics, WebMD Global LLC, Radcliffe Group Ltd and Corpus. NG received board fees from Novartis and honoraria from Boehringer. BP has received personal fees from Bayer, Astra Zeneca , Sanofi, KBP pharmaceuticals *, Sarfez*, scPharmaceuticals*, Cereno *, SQinnovations * , Relypsa/Vifor *, G3 Pharma*and Ardelyx . In addition, BP has a US Patent 99131412-site specific delivery of eplerenone to the myocardium. PR reports personal fees (consulting) from Corvidia, Novartis, NovoNordisk, Relypsa, AstraZeneca, G3P, Grünenthal, Idorsia, Stealth Peptides, Fresenius, Vifor; and lecture fees from Ablative Solutions, Bayer, and CVRx; cofounder of CardioRenal. FZ reports consultancy, trials oversight committees and/or speaker fees from Actelion, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer, Boston Scientific, Cardior, Cereno Scientific AB, CEVA, Cirius Therapeutics, CVRx,, G3 Pharma, GE Healthcare, J&J, Livanova, Merck, Mundipharma, Novartis, NovoNordisk, Pfizer, Quantum Genomics, Relypsa, Resmed, Vifor-Fresenius, ZS Pharma, and is founder of CardioRenal, CVCT and Eshmoun.

* for stock options

References

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* 1999;**341**:709–717.
2. Zannad F, McMurray JJ V, Krum H, Veldhuisen DJ van, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med* 2011;**364**:11–21.
3. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* 2003;**348**:1309–1321.
4. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, TOPCAT Investigators. Spironolactone for Heart Failure with Preserved Ejection Fraction. *N Engl J Med* 2014;**370**:1383–1392.
5. Ferreira JP, Girerd N, Rossignol P, Zannad F. Geographic differences in heart failure trials. *Eur J Heart Fail* 2015;**17**:893–905.
6. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau J-L,

Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. *Circulation* 2015;**131**:34–42.

7. Denus S de, O'Meara E, Desai AS, Claggett B, Lewis EF, Leclair G, Jutras M, Lavoie J, Solomon SD, Pitt B, Pfeffer MA, Rouleau JL. Spironolactone Metabolites in TOPCAT — New Insights into Regional Variation. *N Engl J Med* 2017;**376**:1690–1692.
8. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, Veldhuisen DJ van, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Düngen H-D, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. *N Engl J Med* Massachusetts Medical Society; 2019;**381**:1609–1620.
9. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med* 2014;**371**:993–1004.
10. Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Maaten JM Ter, Metra M, Anker SD, Harst P van der, Ng LL, Meer P van der, Veldhuisen DJ van, Meyer S, Lam CSP, Voors AA, Richards AM, Lam CSP, Anand I, Hung C-L, Ling LH, Liew

HB, Narasimhan C, Ngarmukos T, et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. *Lancet* 2019;**394**:1254–1263.

11. O’Meara E, Clayton T, McEntegart MB, McMurray JJ V, Piña IL, Granger CB, Ostergren J, Michelson EL, Solomon SD, Pocock S, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. *Circulation* 2007;**115**:3111–3120.
12. Martínez-Sellés M, Doughty RN, Poppe K, Whalley GA, Earle N, Tribouilloy C, McMurray JJ V, Swedberg K, Køber L, Berry C, Squire I, Meta-Analysis Global Group In Chronic Heart Failure (MAGGIC). Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. *Eur J Heart Fail* 2012;**14**:473–479.
13. Yancy CW, Fonarow GC, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O’Connor CM, Reynolds D, Walsh MN. Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: Findings from IMPROVE HF. *Am Heart J* 2009;**157**:754–762.
14. Rossello X, Pocock SJ, Julian DG. Long-Term Use of Cardiovascular Drugs. *J Am Coll Cardiol* 2015;**66**:1273–1285.
15. Stolfo D, Uijl A, Vedin O, Strömberg A, Faxén UL, Rosano GMC, Sinagra G,

- Dahlström U, Savarese G. Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications. *JACC Hear Fail* 2019;**7**:505–515.
16. Rickham PP. Human Experimentation. Code Of Ethics Of The World Medical Association. Declaration Of Helsinki. *Br Med J* 1964;**2**:177.
 17. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. *BMJ* 2010;**340**:c221.
 18. Rossello X, Ariti C, Pocock SJ, Ferreira JP, Girerd N, McMurray JJ V., Veldhuisen DJ Van, Pitt B, Zannad F. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. *Clin Res Cardiol* 2019;**108**:477–486.
 19. Costa BR da, Jüni P. Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. *Eur Heart J* 2014;**41**:3336–3345.
 20. Rossignol P, Girerd N, Bakris G, Vardeny O, Claggett B, McMurray JJ V, Swedberg K, Krum H, Veldhuisen DJ van, Shi H, Spanyers S, Vincent J, Fay R, Lamiral Z, Solomon SD, Zannad F, Pitt B. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. *Eur J Heart Fail* 2017;**19**:792–799.
 21. Fischer M, Baessler A, Schunkert H. Renin angiotensin system and gender differences in the cardiovascular system. *Cardiovasc Res* 2002;**53**:672–677.
 22. Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski J, Ceconi C, Drexel H, Kjeldsen K, Savarese G, Torp-Pedersen C, Atar D, Lewis B, Agewall S. Gender

- differences in the effects of cardiovascular drugs. *Eur Hear J - Cardiovasc Pharmacother* 2017;**3**:163–182.
23. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. *JAMA* 1995;**273**:1450–1456.
 24. Rossello X, Ferreira JP, McMurray JJ, Aguilar D, Pfeffer MA, Pitt B, Dickstein K, Girerd N, Rossignol P, Zannad F, High-Risk Myocardial Infarction Database Initiative. Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. *Eur Hear J Acute Cardiovasc Care* 2019;**8**:231–241.
 25. Merrill M, Sweitzer NK, Lindenfeld J, Kao DP. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. *JACC Heart Fail* 2019;**7**:228–238.
 26. Eschalier R, McMurray JJV, Swedberg K, Veldhuisen DJ van, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B. Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function. *J Am Coll Cardiol* 2013;**62**:1585–1593.
 27. Ferreira JP, Abreu P, McMurray JJ V, Veldhuisen DJ van, Swedberg K, Pocock SJ, Vincent J, Lins K, Rossignol P, Pitt B, Zannad F. Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. *Eur J Heart Fail* 2019;**21**:345–351.
 28. Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. *Lancet* 2019;**393**:1034–1044.

29. Iqbal J, Parviz Y, Pitt B, Newell-Price J, Al-Mohammad A, Zannad F. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.

Eur J Heart Fail 2014;**16**:143–150.

Figure legends

Figure 1. Kaplan–Meier survival curve for cardiovascular death (CVD) or heart failure hospitalization (HFH) by gender and treatment arm.

Cumulative time-to-first-event curves for patients randomly assigned to MRA vs placebo by gender. Estimates for men and women are displayed in red and blue, respectively.

Figure 2. Kaplan–Meier survival curves for cardiovascular death (CVD) or heart failure hospitalization (HFH) by gender and treatment arm.

Cumulative time-to-first-event curves for patients randomly assigned to MRA vs placebo by gender in heart failure patients with $LVEF \leq 35\%$ (panel A) and in heart failure patients with $LVEF \geq 45\%$ (panel B).

Figure 3. Forest plot with crude and adjusted HRs for cardiovascular death (CVD) or heart failure hospitalization by gender

Adjusted HRs are plotted in this figure, although both unadjusted and adjusted HR are reported in the right side. Model adjusted for MRA, gender, age, systolic blood pressure, diabetes, hypertension, atrial fibrillation, non-ischemic cause, NYHA class III-IV, LVEF, potassium, estimated glomerular filtration rate, ACEI or ARB, beta-blockers and the interaction (MRA x gender).

Figure 4. Adjusted HRs for cardiovascular death or heart failure hospitalization by gender and other relevant groups

P-values correspond to three-way interactions using the adjusted model – i.e. MRA x gender x diabetes

Tables

Table 1. Baseline clinical features by sex (pooled data across the three trials)

	Male (n=4229)	Female (n=1938)	p-value
Study			
EMPHASIS, n (%)	2127 (50.3%)	610 (31.5%)	<0.001
RALES, n (%)	1217 (28.8%)	446 (23.0%)	
TOPCAT-Americas, n (%)	885 (20.9%)	882 (45.5%)	
Demographic data			
Age (years), mean (SD)	67.8 (9.6)	70.1 (10.1)	<0.001
Age >75 y.o., n (%)	1070 (25.3%)	686 (35.4%)	<0.001
White race, n (%)	3612 (85.4%)	1479 (76.3%)	<0.001
Body mass index (kg/m²), mean (SD)	29.2 (6.1)	31.7 (8.4)	<0.001
Current smoker, n (%)	1168 (38.8%)	170 (11.4%)	<0.001
Vital signs			
Heart rate (bpm), mean (SD)	73.5 (13.9)	73.6 (13.1)	0.730
Systolic blood pressure (mmHg), mean (SD)	123.5 (17.2)	126.9 (18.5)	<0.001
Diastolic blood pressure (mmHg), mean (SD)	73.7 (10.8)	73.6 (11.5)	0.730
Medical history			
Hypertension, n (%)	2441 (57.8%)	1359 (70.1%)	<0.001
Diabetes, n (%)	1354 (32.0%)	661 (34.1%)	0.110
Previous MI, n (%)	1866 (44.2%)	557 (28.7%)	<0.001
Atrial Fibrillation / Flutter, n (%)	1114 (26.5%)	390 (20.2%)	<0.001
COPD, n (%)	675 (16.0%)	234 (12.1%)	<0.001
Heart failure history			
Left ventricular ejection fraction, (%)	32.3 (14.0)	41.7 (18.1)	<0.001
≤35, n (%)	3218 (78.3%)	1024 (53.7%)	<0.001
>45, n (%)	886 (21.6%)	882 (46.3%)	
NYHA class			
II, n (%)	2726 (64.6%)	1153 (59.6%)	<0.001
III-IV, n (%)	1497 (35.5%)	782 (40.4%)	
Previous HF hospitalisation	1653 (54.9%)	826 (55.4%)	0.790
Laboratory tests			
Hemoglobin (g/dL), mean (SD)	13.7 (2.0)	12.6 (2.2)	<0.001
Potassium (mmol/L), mean (SD)	4.3 (0.4)	4.2 (0.5)	<0.001
Sodium (mmol/L), mean (SD)	139.5 (4.4)	139.7 (3.6)	0.190
MDRD eGFR, ml/min/1.73 m²	68.4 (22.9)	62.7 (21.4)	<0.001
MDRD eGFR<60, n (%)	1608 (38.3%)	988 (51.8%)	<0.001
Medications			
ACEI or ARBs, n (%)	3830 (90.6%)	1666 (86.0%)	<0.001
Beta blockers, n (%)	2698 (63.8%)	1224 (63.2%)	0.620
Diuretic, n (%)	3779 (89.4%)	1745 (90.0%)	0.430
Digoxin, n (%)	1292 (38.6%)	442 (41.9%)	0.062
Lipid lowering drug, n (%)	2064 (48.8%)	894 (46.1%)	0.050
Anti thrombotics, n (%)	2892 (68.4%)	1136 (58.6%)	<0.001

ACEI, angiotensin-converting-enzyme-inhibitors; AF, atrial fibrillation; ARB, angiotensin-receptor blockers; BP, blood pressure; COPD, chronic obstructive pulmonary disease; eGFR, estimated Glomerular Filtration Rate; HF, heart failure; LVEF, left ventricular ejection fraction; MDRD, Modification of Diet in Renal Disease; MI, myocardial infarction; MRA; mineral receptor antagonist; NYHA, New York Heart Association

Table 2. Time at risk, number of events and estimated incidence rates (95% CI) for the primary endpoint (cardiovascular mortality or heart failure hospitalization)

	Total person-time at risk	Number of events	Incidence rate (95% CI)	Incidence rate ratio (95% CI)	Absolute difference in rates (95% CI)
HFrEF (RALES+EMPHASIS-HF)					
Male-Placebo	2528.7	648	25.6 (23.7-27.7)	0.67 (0.59-0.75)	8.5 (6.0-11.0)
Male-MRA	2755.1	471	17.1 (15.6-18.7)		
Female-Placebo	788.3	200	25.4 (22.1-29.1)	0.61 (0.49-0.77)	9.8 (5.4-14.1)
Female-MRA	897.5	140	15.6 (13.2-18.4)		
HFpEF (TOPCAT-Americas)					
Male-Placebo	1081.9	150	13.9 (11.8-16.3)	0.82 (0.65-1.05)	2.5 (-0.5-5.4)
Male-MRA	1149.6	131	11.3 (9.5-13.5)		
Female-Placebo	1146.9	130	11.4 (9.6-13.5)	0.81 (0.63-1.06)	2.1 (-0.5-4.7)
Female-MRA	1204.4	111	9.2 (7.7-11.1)		
Overall					
Male-Placebo	3610.5	798	22.1 (20.6-23.7)	0.70 (0.63-0.78)	6.7 (4.7-8.7)
Male-MRA	3904.7	602	15.4 (14.2-16.7)		
Female-Placebo	1935.2	330	17.1 (15.3-19.0)	0.70 (0.59-0.83)	5.1 (2.8-7.5)
Female-MRA	2101.9	251	11.9 (10.6-13.5)		

By-trial and overall estimated incidence rates and absolute differences in rates for the primary endpoint. Total person-time at risk is expressed in 100 person-year.

Table 3. Time at risk, number of events and estimated incidence rates (95% CI) for the secondary endpoint (cardiovascular death)

	Total person-time at risk	Number of events	Incidence rate (95% CI)	Incidence rate ratio (95% CI)	Absolute difference in rates (95% CI)
HFrEF (RALES+EMPHASIS-HF)					
Male-Placebo	2958.7	402	13.6 (12.3-15.0)	0.75 (0.65-0.87)	3.4 (1.6-5.1)
Male-MRA	3046.7	311	10.2 (9.1-11.4)		
Female-Placebo	939.1	121	12.9 (10.8-15.4)	0.66 (0.49-0.87)	4.4 (1.5-7.4)
Female-MRA	994.1	84	8.5 (6.8-10.5)		
HFpEF (TOPCAT-Americas)					
Male-Placebo	1271.1	69	5.4 (4.3-6.9)	0.79 (0.55-1.14)	1.1 (-0.01-2.8)
Male-MRA	1302.7	56	4.3 (3.3-5.6)		
Female-Placebo	1331.8	58	4.4 (3.4-5.6)	0.68 (0.44-1.03)	1.4 (0.0-2.9)
Female-MRA	1360.5	40	2.9 (2.2-4.0)		
Overall					
Male-Placebo	4229.8	471	11.1 (10.2-12.2)	0.76 (0.66-0.87)	2.7 (1.3-4.0)
Male-MRA	4349.4	367	8.4 (7.6-9.3)		
Female-Placebo	2270.9	179	7.9 (6.8-9.1)	0.67 (0.53-0.84)	2.6 (1.1-4.1)
Female-MRA	2354.5	124	5.3 (4.4-6.3)		

By-trial and overall estimated incidence rates and absolute differences in rates for cardiovascular mortality. Total person-time at risk is expressed in 100 person-year.

Table 4. Time at risk, number of events and estimated incidence rates (95% CI) for the secondary endpoints all-cause death

	Total person-time at risk	Number of events	Incidence rate (95% CI)	Incidence rate ratio (95% CI)	Absolute difference in rates (95% CI)
HFrEF (RALES+EMPHASIS-HF)					
Male-Placebo	2958.7	460	15.5 (14.2-17.0)	0.76 (0.66-0.87)	3.7 (1.9-5.6)
Male-MRA	3046.7	360	11.8 (10.7-13.1)		
Female-Placebo	939.1	139	14.8 (12.5-17.5)	0.66 (0.50-0.86)	5.0 (1.9-8.2)
Female-MRA	994.1	97	9.8 (8.0-11.9)		
HFpEF (TOPCAT-Americas)					
Male-Placebo	1271.1	107	8.4 (7.0-10.2)	1.02 (0.78-1.34)	-0.2 (-2.4-2.1)
Male-MRA	1302.7	112	8.6 (7.1-10.3)		
Female-Placebo	1331.8	98	7.4 (6.0-9.0)	0.70 (0.51-0.96)	2.2 (0.3-4.1)
Female-MRA	1360.5	70	5.1 (4.1-6.5)		
Overall					
Male-Placebo	4229.8	567	13.4 (12.3-14.6)	0.81 (0.71-0.92)	2.5 (1.14-0)
Male-MRA	4349.4	472	10.9 (9.9-11.9)		
Female-Placebo	2270.9	237	10.4 (9.2-11.9)	0.68 (0.55-0.83)	3.3 (1.6-5.1)
Female-MRA	2354.5	167	7.1 (6.1-8.3)		

By-trial and overall estimated incidence rates and absolute differences in rates for all-cause mortality. Total person-time at risk is expressed in 100 person-year.

Table 5. Side effects within treatment arm by sex (pooled data across the three trials)

	MRA			Placebo			p for interaction
HFrEF (RALES+EMPHASIS-HF)	Male (n=1,658)	Female (n=528)	p- value	Male (n=1,686)	Female (n=528)	P-value	
Hyperkalemia, n (%)	241 (14.9%)	71 (1.0%)	0.617	115 (7.0%)	37 (7.2%)	0.891	0.683
Worsening renal function, n (%)	446 (28.9%)	165 (33.7%)	0.040	311 (20.0%)	123 (25.3%)	0.012	0.630
HFpEF (TOPCAT-Americas)	Male (n=444)	Female (n=442)	p- value	Male (n=441)	Female (n=440)	P-value	
Hyperkalemia, n (%)	73 (16.5%)	68 (15.4%)	0.657	22 (5.0%)	24 (5.5%)	0.762	0.625
Worsening renal function, n (%)	175 (39.4%)	214 (48.5%)	0.006	129 (29.3%)	160 (36.4%)	0.025	0.811
Overall	Male (n=2,102)	Female (n=970)	p- value	Male (n=2,127)	Female (n=968)	P-value	
Hyperkalemia, n (%)	314 (15.2%)	139 (14.7%)	0.679	137 (6.6%)	61 (6.4%)	0.840	0.944
Worsening renal function, n (%)	621 (31.2%)	379 (40.8%)	<0.001	440 (22.0%)	283 (30.6%)	<0.001	0.813

Hyperkalemia was defined as any laboratory value of serum potassium above 5.5 mmol/L during the follow-up. Worsening renal function was defined as an estimated glomerular filtration rate drop greater than 30% during the follow-up. Within gender comparison were made using the chi-square test, whereas differences in adverse event effects were tested using the interaction (MRA * gender) in a logistic regression. The hypothesis of little heterogeneity is also supported by the Wald test for overall interaction study x treatment x gender for both hyperkalemia (p = 0.85) and worsening renal function (p = 0.84).






fig 1 - km - gender r1.eps



Number at risk	0	1	2	3
Male-Placebo	1686	1017	591	180
Female-Placebo	528	317	188	55
Male-MRA	1658	1136	663	195
Female-MRA	528	365	237	68



Number at risk	0	1	2	3
Male-Placebo	440	346	239	144
Female-Placebo	440	357	264	166
Male-MRA	444	365	244	166
Female-MRA	441	370	278	168

fig 2 - km - gender r1.eps




fig 3 - fplot - gender r1.eps




fig 4 - fplot - gender r1.eps

The material contained in this paper has not been previously published and it is not under consideration for publication in any journal. All authors have read and approved the present version of the manuscript.

Author Manuscript